35 th Annual J.P. Morgan Healthcare Conference. Gwan Sun Lee. President & CEO

Transcription

1 35 th Annual J.P. Morgan Healthcare Conference Gwan Sun Lee President & CEO

2 This presentation contains forward-looking statements with respect to the financial condition, results of operations and businesses of Hanmi Pharmaceutical Company. By their nature, forw ard-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, the loss or expiration of patents, marketing exclusivity or trade marks; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of delay to new product launches; the difficulties of obtaining and maintaining governmental approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as we expect; and the risk of environmental liabilities. 2

3 Acquisition in June

4 PAST PRESENT FUTURE Strong cash flow from traditional pharma business through our own valueadded products & generics Heavy investment in innovation R&D from the early 2000s Robust pipeline from in-house R&D as well as open innovation Leading in our core businesses in Korea & China Investment in the highestpotential business To be a global R&D powerhouse through continuous new drug discovery & development in core therapeutic areas To significantly grow through innovative new drugs 4

5 Diabetes Obesity Oncology Auto-immune 5

6 Diabetes Obesity Oncology Auto-immune B B Others B 6

7 Next generation bispecific antibody platform technology, developed by Beijing Hanmi for both immunotherapy & targeted therapy Immune cell Tumor cell Key Features Redirect immune cells to tumor cells Natural IgG-like bispecific antibody format P E N T O B D Y Good stability and high production efficiency Seeking collaboration opportunities (PENTAMBODY + Novel target) A M 7

8 Redirect immune cells to tumor cells Better anti-tumor activity compared to combination Pentambody applied PD-1/HER2 BsAb Cell-to-cell association (%) using SK-BR-3 and CHO-PD1 cells by FACS 1 Pentambody applied PD-1/PD-L1 BsAb Cell cytotoxicity assay using PD-L1 expressed NSCLC cell 2 Anti-PD-L1 mab: IC 50 >2,000 pm Anti-PD-1 mab: IC pm Combination: IC pm PD-1/PD-L1 BsAb (BH2941): IC pm 1 HER2 positive SK-BR-3 stained with CFSE, CHO-PD1 stained with PKH26, Test article 100nM, 30min; 2 E (activated hpbmc) : T (HCC827) = 20 : 1, 72hr 8

9 AGLYCOSYLATED FC AGLYCOSYLATED FC LAPSCOVERY : Long-Acting Protein/Peptide Discovery 8 Programs LAPS GCSF LAPS hgh LAPS Insulin115 5 Clinical programs 3 Non-clinical programs LAPS Exd4 LAPS GLP/GCG LAPS Insulin combo Diabetes/Obesity Program Rare Disease Program 3 Focus Areas Diabetes Obesity Rare Diseases (enzyme) Seeking new opportunities by expanding indications 9

10 LAPS is the best long-acting solution for ERT PK extension with best-in-class potential (Subcutaneous self administration) Higher exposure & tissue delivery 10

11 HM95573, pan-raf inhibitor Exclusive License Agreement with Genentech (Sep 2016) Upfront : USD 80M / Milestones : up to USD 830M / Tiered double-digit royalty An orally active, selective and potent next generation RAF inhibitor with anti-tumor effect on BRAF mutant as well as RAS mutant cancer A variety of science-driven combinations will be assessed, as well as monotherapy 11

12 olmutinib Quantum Project 3 rd generation EGFR targeted therapy NDA approved and commercialized in Korea in May 2016 A portfolio of long-acting diabetes treatments : 1) efpeglenatide, 2) weekly insulin, and 3) efpeglenatide/weekly insulin combo Boehringer Ingelheim returned Sanofi is responsible for the development development and global commercial rights and commercialization of efpeglenatide of olmutinib to Hanmi in Sep 2016 Sanofi returned its rights to Hanmi weekly In China, IND submitted to CFDA by our insulin in Dec 2016 partner, Zai Lab Hanmi will continue its efforts, in solid Seeking opportunities for global cooperation with Sanofi, for the collaboration development and commercialization of efpeglenatide/weekly insulin combo 12

13 Korea Sustain double-digit growth through new value-added programs with data exclusivity China Maintain a profitable performance with Beijing Hanmi s key brands Seek synergies with JVM Emerging market Expand market access and enhance sales for value-added programs through partnership & collaboration US / Europe Continue our effort to develop and commercialize Hanmi s innovative R&D pipeline with partners 13

14 Driving growth and delivering profits with new products Capacity expansion for future global business 8.8% 15.3% * 1+3 2B max. 10B Double-digit Rx Growth in 2016 New Products Launch 1 NCE & 3 valueadded products CAPEX Completion of New Plant at Paltan site *Ubist, YOY growth rate of accumulated Rx until Nov

15 Launching 2~3 products annually in the domestic market 8 new products under development Seeking partners for emerging market business Rosuzet Collaboration with MSD for 23 countries *Incrementally Modified Drug **Fixed Dose Combination 15

16 Performance R&D Expand Local Partnerships Sustain No.1 position in Focus on innovative R&D Fast & successful pediatric market for global development development in collaboration Maintain profits from key strategy with local partners with in- brands 160 R&D staffs depth understanding of Business diversification New platform technology Chinese market through JVM s products Pentambody 16

17 Hanmi Science acquired JVM in Jun 2016 Global No.1 company making automated system for hospitals & pharmacies JVM s competitive technology to create new value to Hanmi group Sales and distribution by Online Pharm R&D & manufacture by JVM Beijing Hanmi will act as the operation hub for JVM Chinese business Build new business structure to maximize synergistic effect 17

18 To be more efficient and effective 18

19 19

20 Thank you